Semperit (SEM) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Revenue declined 7.2% year-over-year to EUR 320.5 million in H1 2025, with EBITDA down 35.2% to EUR 30.7 million and earnings after tax negative at EUR -11.2 million.
Q2 2025 saw a significant EBITDA improvement to EUR 19.6 million, up 77% quarter-on-quarter, but not enough to offset a weak Q1.
Order intake and backlog improved from March onward, exceeding last year's levels, supported by Q2 recovery.
Strong balance sheet maintained with equity ratio at 45.5%–46% and cash reserves of EUR 112.9–113 million.
Market uncertainty, especially from US tariffs and project delays, delayed customer investments.
Financial highlights
H1 2025 EBITDA margin was 9.6% (down 4.1pp), EBIT margin 0.8% (down 6.0pp), and EPS at EUR -0.54.
Free cash flow was EUR 13.9 million; CapEx reduced by over 50% to EUR 18.5 million.
Net financial debt increased to EUR 118.6 million; leverage ratio at 1.7x EBITDA.
Dividend of EUR 0.50 per share (EUR 10.3 million) paid in April 2025.
EBIT dropped 88.8% to EUR 2.6 million; return on equity at -5.6%.
Outlook and guidance
Operating EBITDA for 2025 is guided at EUR 65–85 million, with EUR 5 million in digitalization project costs.
CapEx for 2025 expected at EUR 50 million, with flexibility to adjust to market conditions.
Recovery expected in H2 2025, but high uncertainty remains due to US tariffs and market conditions.
Medium-term drivers include EU infrastructure programs and rising defense expenditures.
Actively screening for inorganic growth and acquisition opportunities.
Latest events from Semperit
- EBITDA more than doubled on 11.1% revenue growth, with guidance raised despite H2 cost risks.SEM
Q2 2026 - Q1 2026 saw strong revenue and EBITDA growth, but geopolitical and raw material risks remain.SEM
Q1 2026 - Margin recovery, innovation, and sustainability drive a strong 2026 growth outlook.SEM
Austrian Select Conference - Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 2025 - Q3 2025 saw a strong EBITDA rebound and positive earnings, supporting a robust full-year outlook.SEM
Q3 2025 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 2024 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 2024 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 2025 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 2024